News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ablynx is Granted Extended GMP Certificate for New GMP Unit



1/11/2012 9:25:22 AM

GHENT, BELGIUM--(Marketwire - January 10, 2012) -



GHENT, Belgium, 10 January 2012 - Ablynx [Euronext Brussels: ABLX] today announced that it has been granted an extended Certificate of Good Manufacturing Practice (GMP) from the Federal Agency for Medicines and Health Products (FAMHP) in Belgium for its new GMP unit at its headquarters in Ghent, after having been inspected in November 2011.

Having received this accreditation, Ablynx's GMP unit will now perform release- testing on Drug Substance and Drug Product batches and independently perform all stability studies on these batches. The large scale GMP manufacturing of Nanobodies® will continue to be outsourced to contract manufacturing organisations (CMO).

Dr Edwin Moses, CEO and Chairman of Ablynx, commented: "GMP certification of our laboratories in Ghent is a testament to Ablynx's commitment to consistently perform at a high standard in our internal and partnered development programmes. This is an important step forward as we continue to transform into a product- based company."


About Good Manufacturing Practice

Good Manufacturing Practice (GMP) is that part of a Quality Management System which ensures that products are consistently produced and controlled to the quality standards appropriate to their intended use.


About the Federal Agency for Medicines and Health Products

The Federal Agency for Medicines and Health Products (FAMHP) is the competent authority responsible for the quality, safety and efficacy of medicines and health products in Belgium.


About Ablynx

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies(®), a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has over 25 programmes in the pipeline and seven Nanobodies in clinical development. Ablynx has ongoing research collaborations and significant partnerships with major pharmaceutical companies, including Boehringer Ingelheim, Merck Serono, Novartis, and has had a collaboration with Pfizer. The Company is headquartered in Ghent, Belgium and currently employs over 290 people. More information can be found on www.ablynx.com.


Complete version of the press release: http://hugin.info/137912/R/1576511/491346.pdf




This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Ablynx via Thomson Reuters ONE

[HUG#1576511]


For more information, please contact Ablynx:

Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
e: Email Contact

Marieke Vermeersch
Investor Relations Manager
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: Email Contact


Read at BioSpace.com


comments powered by Disqus
Ablynx
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES